RecruitingPhase 2NCT06718244

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Studying Precursor B-cell acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Intervention
single dose of Inaticabtagene autoleucel(biological)
Enrollment
20 enrolled
Eligibility
16-70 years · All sexes
Timeline
20242029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06718244 on ClinicalTrials.gov

Other trials for Precursor B-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Precursor B-cell acute lymphoblastic leukemia

← Back to all trials